# Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

> **NCT00671697** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 13 (actual)

## Conditions studied

- Myelodysplastic Syndromes and Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Arsenic Trioxide
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT00671697
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-01
- **Final completion:** 2011-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2013-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671697, "Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00671697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*